China’s Impact Therapeutics raises $10m Series B round

Chinese drug development startup, Impact Therapeutics, has raised $10 million in fresh funding, the company said in a disclosure.

New investors in the series B round include China Summit Capital, Guangzhou Yuexiu Industrial Investment Fund, Sungent Bioventure and Haibang Ventures. Existing investor Lilly Asia Ventures also participated.

“We are very pleased with the strong support from leading life science investment firms in this financing round, and are in a strong position to advance clinical studies of multiple programs,” said Dr. Edward Tian, chief executive officer, Impact.

Tian was previously with the research and development units of Pfizer Inc and Transtech Pharma in the US for more than two decades.

The Nanjing-based company had last raised funding in a series A round led by Lilly Asia Ventures, Cenova Capital and Wuxi AppTec Ventures.

Impact has established a research and business platform for the discovery and development of anti-cancer drugs. It has been testing anti-tumor drugs in pre-clinical and later stages.

Also read:

Ratan Tata invests in Delhi-based Invictus Oncology

Pharma giants GSK, AstraZeneca, J&J tap UK universities with $57m drug research fund

Temasek increases stake in Portola Pharmaceuticals

 

 

 

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.